UBS Group Boosts Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Price Target to $22.00

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) had its target price boosted by research analysts at UBS Group from $21.00 to $22.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price objective points to a potential upside of 18.28% from the company’s previous close.

Separately, William Blair raised Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research report on Tuesday, November 19th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Up 2.0 %

Shares of NASDAQ TLX traded up $0.36 during trading on Monday, hitting $18.60. 17,251 shares of the company were exchanged, compared to its average volume of 12,207. Telix Pharmaceuticals Limited American Depositary Shares has a 12-month low of $14.01 and a 12-month high of $19.99. The company’s fifty day moving average is $15.81.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.